Durin Technologies, Inc., a Stratford, NJ-based innovator in neurodegenerative disease diagnostic test development and commercialization, raised $3.5m in funding.
The round was led by Breakthrough Diagnostics, LLC.
The company intends to use the funds to accelerate its next key stages of growth, involving commercialization of its novel diagnostic tests focusing on Alzheimer’s and Parkinson’s diseases and development of its diagnostic tests that detect other diseases and disorders at their earliest stages.
Led by CEO Mert Sahin, Ph.D., Durin Technologies develops non-invasive, easy access diagnostic tests for the most prevalent and devastating neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Its rapid-result, high-accuracy DuritectTM diagnostic tests make early detection and monitoring of disease progression possible – in a decade or more prior to symptoms in some cases. Durin’s first two tests – for Alzheimer’s and Parkinson’s – will come to market in 2024, followed by tests for other diseases.
FinSMEs
05/12/2023